Investigation of the gut microbiota and adverse reactions associated with the combined bifidobacterium, lactobacillus, enterococcus and bacillus cereus tablets and rabeprazole in patients suffering from gastroesophageal reflux

ABSTRACT

Objective: To explore the effect of proton pump inhibitor (PPI) Rabeprazole combined with Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus cereus Tablets (CBLEB) in gastroesophageal reflux disease (GERD) on the regulation of gut microbiota and alleviation of gastrointestinal adverse reactions. Methods: A total of 60 patients with gastroesophageal reflux admitted to the Department of Gastroenterology of the Second Affiliated Hospital of Xuzhou Medical University from December 2022 to December 2023 were selected as the research subjects, and they were randomly divided into the Experiment group (rabeprazole + CBLEB) and the Control group (rabeprazole) by random number table method, and the general information and inflammatory factor levels of the two groups were compared, and the incidence of gastrointestinal adverse reactions and GerdQ score were compared between the control group and the experimental group. Results: The comparison of various data of subjects in the two groups showed that there were no significant differences in basic data such as age, body mass index and gender distribution between the control group and the experimental group. After treatment, bifidobacteria and lactobacillus in the experimental group were significantly increased in the control group, while GerdQ score in the experimental group was significantly lower than that in the control group, with statistical significance (P<0.05). The incidence of adverse reactions in control group was significantly higher than that in experimental group, the difference was statistically significant (P<0.05), CRP and GerdQ score were linearly correlated. Conclusion: CBLEB can improve the disturbance of gastrointestinal microbiota in GERD patients and alleviate gastrointestinal adverse reactions caused by PPI use.

KEYWORDS

• Gastroesophageal reflux
• Probiotics
• Rabeprazole
• Gut microbiota

Showing references and in-text citations exactly as published.

• DOI10.18549/PharmPract.2025.4.3225Copy

RELATED ARTICLES

Matched on section and article type within this issue of PP.

• Article · VOLUME 23, ISSUE 4Quercetin encapsulated polymeric nanomicelles substantially chemosensitising antiproliferation by branched chain amino acids with enhanced antiinflammation capacities: A new strategy against adherent cancer monolayersViolet Kasabri, Suhair Sunoqrot, Rasha Al-Motassem, Yusuf Al-Hiari, Riad Ababneh, Balqis Ikhmais, Hamza AbuMansour, Dalya Al-Saad, Dana Shalabi, Rema Alkhateeb · pp. 1–10Original ResearchSame type: Article
• Article · VOLUME 23, ISSUE 4Conservation of Medicinal plants by sustainable aquaponics approach for novel drug developmentRamya Manoharan, Chythra Somanathan Nair, Drishya Nishanth, Radhakrishnan Subramanian, Xiulan Xie, Maozhi Ren, Abdul Jaleel · pp. 1–16Original ResearchSame type: Article
• Article · VOLUME 23, ISSUE 4Fostering empathy and social responsibility in pharmacy students through experiential service-learning: A qualitative studySabeena Salam, Semira Beshir, Sadaf Sana, Faizah Hussain, Aliasgar Shahiwala · pp. 1–8Original ResearchSame type: Article
• Article · VOLUME 23, ISSUE 4An investigative assessment on the quality of community pharmacy practice in the United Arab Emirates using common cold scenarioSubish Palaian, Muaed Alomar, Nageeb Hassan, Mukhtar Ansari · pp. 1–8Original ResearchSame type: Article